Thomas F. Gajewski to Response Evaluation Criteria in Solid Tumors
This is a "connection" page, showing publications Thomas F. Gajewski has written about Response Evaluation Criteria in Solid Tumors.
Connection Strength
0.079
-
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann Oncol. 2019 04 01; 30(4):589-596.
Score: 0.041
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.038